CaPP3 Australia

posted on Thursday, 8th February 2018

Not tagged.

[#pageName]

From left to right: Finlay Macrae, Zafirah Khan (CaPP3 Research Coordinator at the Royal Melbourne Hospital) and John Burn

CaPP3 Australia opened to recruitment at the Royal Melbourne Hospital in May 2017 and the Kinghorn Cancer Centre, Sydney in March 2018, and has recruited 138 study participants (13.03.19).

The study is led by Professor Finlay Macrae, at the Royal Melbourne Hospital, who hopes to be able to recruit 150 study participants from Melbourne and other centres around Australia.

Professor Sir John Burn, the Chief Investigator of  CaPP3 visited the team at the Royal Melbourne Hospital in September 2017 when he spoke at the Victorian Comprehensive Cancer Centre (VCCC) Inaugural Research Conference.   

Share this!

Latest News

  • 16

    Jun

    2020

    COVID-19 and aspirin

    posted on Tuesday, 16th June 2020

    In March 2020 there were reports which indicated a possible link with taking non-steroidal anti-inflammatory drugs (NSAIDs), which include ibuprofen and aspirin, and the severity of Covid-19.

    Not tagged.

    Comments (0)

  • 15

    Jun

    2020

    CAPP2 in the Lancet

    posted on Monday, 15th June 2020
    CAPP2 in the Lancet

    The CAPP2 long term follow up paper is now published

    Not tagged.

    Comments (0)

Downloads